| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Y J Debets-Ossenkopp | |
| A Beishuizen | |||
| A B J Groeneveld | |||
| A R J Girbes | |||
| R J Trof | |||
| P2860 | cites work | Voriconazole therapeutic drug monitoring. | Q24542411 |
| Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome | Q24811601 | ||
| CT signs and patterns of lung disease | Q28204293 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans | Q28265703 | ||
| Invasive aspergillosis in immunocompromised patients: findings on plain film and (HR)CT | Q57891159 | ||
| Rapidly progressive respiratory failure due to Aspergillus pneumonia | Q57895511 | ||
| Multiple-Triazole–Resistant Aspergillosis | Q63914862 | ||
| Nosocomial outbreak of Aspergillus fumigatus infection among patients in a renal unit? | Q71164310 | ||
| Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease | Q71395563 | ||
| Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones | Q71654513 | ||
| Disseminated aspergillosis after near-drowning | Q72000418 | ||
| Immunologic effects of acute hyperglycemia in nondiabetic rats | Q73184448 | ||
| Diagnosis of pulmonary aspergillosis using optical brighteners | Q73520140 | ||
| Amphotericin B both inhibits and enhances T-cell proliferation: inhibitory effect is mediated through H(2)O(2) production via cyclooxygenase pathway by macrophages | Q73666888 | ||
| Aspergillus airway colonization and invasive disease after lung transplantation | Q73875975 | ||
| Detection of Aspergillus galactomannan antigen in foods and antibiotics | Q74200091 | ||
| Aspergillus detection in bronchoscopically acquired material. Significance and interpretation | Q77418828 | ||
| Polymerase chain reaction on blood for the diagnosis of invasive pulmonary aspergillosis in cancer patients | Q77838929 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients | Q80536933 | ||
| A case of invasive pulmonary aspergillosis in renal failure | Q80607959 | ||
| Aspergillosis in the ICU - The new 21st century problem? | Q92929057 | ||
| Invasive pulmonary aspergillosis: frequency and meaning of the "hypodense sign" on unenhanced CT. | Q53576056 | ||
| Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. | Q53840579 | ||
| Invasive pulmonary aspergillosis: prediction at thin-section CT in patients with neutropenia--a prospective study. | Q53946877 | ||
| Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. | Q54071912 | ||
| Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. | Q54116723 | ||
| Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. | Q54251450 | ||
| The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. | Q54622007 | ||
| Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: Report of Eight Cases and Review | Q57238104 | ||
| Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | Q28277029 | ||
| Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 | ||
| Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis | Q28377349 | ||
| Echinocandin antifungal drugs | Q29398696 | ||
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy | Q33257899 | ||
| Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series | Q33271183 | ||
| The effects of injury on the adaptive immune response | Q33585398 | ||
| Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon | Q33614894 | ||
| Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 | ||
| Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. | Q33964096 | ||
| Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model | Q33981712 | ||
| Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group | Q34002098 | ||
| Rationale for combination antifungal therapy | Q34335236 | ||
| Nosocomial aspergillosis is waterborne | Q34378311 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis | Q34514484 | ||
| Assessing risk factors for systemic fungal infections | Q34517136 | ||
| Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon | Q34563875 | ||
| Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients | Q34630182 | ||
| Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis | Q34990623 | ||
| Itraconazole resistance in Aspergillus fumigatus | Q35136791 | ||
| Th1 and Th2 cytokines in mice with invasive aspergillosis. | Q35567104 | ||
| Status of combination therapy for refractory mycoses | Q35587115 | ||
| Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. | Q35595414 | ||
| Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis | Q35636789 | ||
| Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients | Q35913870 | ||
| Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients | Q35923365 | ||
| CT halo sign: the spectrum of pulmonary diseases | Q36234620 | ||
| The radiological spectrum of pulmonary aspergillosis | Q36235123 | ||
| Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy | Q36257693 | ||
| Laboratory diagnosis of invasive aspergillosis. | Q36267587 | ||
| The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis | Q36278972 | ||
| Pharmacokinetic/pharmacodynamic profile of voriconazole | Q36520587 | ||
| Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. | Q36521719 | ||
| Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies | Q36526353 | ||
| Invasive pulmonary and central nervous system aspergillosis after near-drowning of a child: case report and review of the literature | Q36545593 | ||
| Treatment options of invasive fungal infections in adults | Q36579651 | ||
| Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome | Q36686780 | ||
| False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment | Q37597610 | ||
| Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid | Q37702655 | ||
| Risk factors for nosocomial infection in intensive care. 'Devices vs nature' and goals for the next decade | Q38598619 | ||
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 | ||
| The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients | Q40565864 | ||
| Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients | Q40572100 | ||
| Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients | Q40585861 | ||
| Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients | Q41998776 | ||
| Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. | Q42833328 | ||
| T cell vaccination in mice with invasive pulmonary aspergillosis. | Q43413736 | ||
| Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? | Q43561043 | ||
| Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors | Q43790539 | ||
| Immunoparalysis as a cause for invasive aspergillosis? | Q43798573 | ||
| Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in BAL. | Q43955608 | ||
| Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin | Q44304226 | ||
| Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 | ||
| Acute invasive pulmonary aspergillosis in chronic lung disease--a review | Q44469494 | ||
| Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 | ||
| Amphotericin B: time for a new "gold standard". | Q44527998 | ||
| Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis | Q44548714 | ||
| Liver failure in a child receiving highly active antiretroviral therapy and voriconazole | Q44573512 | ||
| Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). | Q44589098 | ||
| Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants | Q44606439 | ||
| False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. | Q44688423 | ||
| Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants | Q44777583 | ||
| False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. | Q44785839 | ||
| Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies | Q44785842 | ||
| Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient | Q44919437 | ||
| Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. | Q45051224 | ||
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome | Q45268727 | ||
| Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay | Q46503389 | ||
| Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study | Q46943408 | ||
| Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis | Q47561157 | ||
| Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. | Q47799923 | ||
| Clinical significance of lower respiratory tract Aspergillus culture in elderly hospitalized patients | Q47981565 | ||
| Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence | Q47997226 | ||
| Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam | Q48710479 | ||
| Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality | Q49124894 | ||
| Invasive pulmonary aspergillosis after near-drowning | Q50123242 | ||
| Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. | Q51191494 | ||
| The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. | Q51191763 | ||
| Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. | Q51192216 | ||
| P433 | issue | 10 | |
| P921 | main subject | aspergillosis | Q259626 |
| invasive pulmonary aspergillosis | Q54946623 | ||
| P304 | page(s) | 1694-1703 | |
| P577 | publication date | 2007-07-24 | |
| 2007-10-01 | |||
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients | |
| P478 | volume | 33 |
| Q34559978 | Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes |
| Q53664904 | Aspergillus infection and extracorporeal membrane oxygenation support. |
| Q30361624 | Aspergillus infections in transplant and non-transplant surgical patients |
| Q33754548 | CD8⁺ T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis |
| Q41728619 | Chronic necrotising pulmonary aspergillosis: an uncommon aetiology of pneumothorax |
| Q84072939 | Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report |
| Q36240843 | Development of Aspergillosis in a cohort of non-neutropenic, non-transplant patients colonised by Aspergillus spp. |
| Q51348218 | Diagnostic criteria for invasive pulmonary aspergillosis in critically ill patients. |
| Q39705805 | Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig. |
| Q39473672 | Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. |
| Q40215717 | Endomyocardial and pericardial aspergillosis in critically ill patients |
| Q38328091 | Eosinophil deficiency compromises lung defense against Aspergillus fumigatus |
| Q30367762 | Fatal clinical course of probable invasive pulmonary aspergillosis with influenza B infection in an immunocompetent patient. |
| Q42872306 | Fluorescence Polarization Binding Assay for Aspergillus fumigatus Virulence Factor UDP-Galactopyranose Mutase |
| Q33356259 | Hospital-acquired invasive pulmonary aspergillosis in patients with hepatic failure |
| Q26999448 | How to manage aspergillosis in non-neutropenic intensive care unit patients |
| Q37780755 | ICU-acquired immunosuppression and the risk for secondary fungal infections. |
| Q40088340 | Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation |
| Q34129471 | Immunoproteomics based identification of thioredoxin reductase GliT and novel Aspergillus fumigatus antigens for serologic diagnosis of invasive aspergillosis |
| Q43759764 | Incidence of pulmonary aspergillosis and correlation of conventional diagnostic methods with nested PCR and real-time PCR assay using BAL fluid in intensive care unit patients. |
| Q33810700 | Innate Lung Defense during Invasive Aspergillosis: New Mechanisms |
| Q91911829 | Insuffisance Respiratoire Aiguë chez le patient immunodéprimé : Quelle approche diagnostique ? |
| Q90636967 | Invasive Aspergillosis After Non-Fatal Drowning |
| Q36906082 | Invasive Aspergillus infections in hospitalized patients with chronic lung disease |
| Q44610230 | Invasive aspergillosis in the ICU: an emerging disease |
| Q38066616 | Invasive aspergillosis in the intensive care unit |
| Q37643057 | Invasive fungal infections in the ICU. |
| Q44020369 | Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). |
| Q39206915 | Invasive mould infections in the ICU setting: complexities and solutions |
| Q35756322 | Invasive pulmonary aspergillosis accompanied by soft tissue lesions during treatment of a patient with hyperthyroidism: a case report |
| Q41857104 | Invasive pulmonary aspergillosis after influenza a infection in an immunocompetent patient |
| Q40271865 | Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects |
| Q51176004 | Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease. |
| Q46106820 | Invasive pulmonary aspergillosis. Occurrence in a non-neutropenic female patient with abdominal sepsis |
| Q46246507 | Modulation of Immune Signaling and Metabolism Highlights Host and Fungal Transcriptional Responses in Mouse Models of Invasive Pulmonary Aspergillosis |
| Q33610419 | Multiple cavities with halo sign in a case of invasive pulmonary aspergillosis during therapy for drug-induced hypersensitivity syndrome |
| Q52649901 | New insights into the clinical characteristics and prognostic factors of pulmonary fungal infections from a retrospective study in Southwestern China. |
| Q59356608 | Pathogenic Fungal Species Associated with Digestive System of (Blattaria: Blattidae) Trapped from Residential Dwellings in Ahvaz City, Southwestern Iran |
| Q91950206 | Potential value of serum Aspergillus IgG antibody detection in the diagnosis of invasive and chronic pulmonary aspergillosis in non-agranulocytic patients |
| Q40164347 | Pseudomembranous aspergillar tracheobronchitis in a non-neutropenic critically ill patient in the intensive care unit |
| Q40675467 | Pulmonary Fungal Diseases in Immunocompetent Hosts: A Single-Center Retrospective Analysis of 35 Subjects |
| Q53390731 | Pulmonary exposure to soluble cell wall beta-(1, 3)-glucan of aspergillus induces proinflammatory response in mice. |
| Q51511753 | Quantitative Real-Time PCR and Platelia Galactomannan Assay for the Diagnosis of Invasive Pulmonary Aspergillosis: Bronchoalveolar Lavage Fluid Performs Better Than Serum in Non-neutropaenic Patients. |
| Q31106825 | Repeated Aspergillus isolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection? |
| Q83828828 | Risk factors and clinical outcomes of ventilator-associated pneumonia in patients on the liver transplant waiting list |
| Q37606127 | The biocontaminants and complexity of damp indoor spaces: more than what meets the eyes |
| Q38679742 | Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses |
| Q43191432 | Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine |
| Q37966018 | Year in review 2010: Critical Care--Infection |
| Q81193460 | [Epidemiology of and risk factors for invasive aspergillosis in nonneutropenic patients] |
Search more.